No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
JAKK Jakks Pacific
- 17.430
- -1.110-5.99%
Close Jun 18 16:00 ET
- 17.510
- +0.080+0.46%
Post 19:41 ET
188.26MMarket Cap6.25P/E (TTM)
18.410High17.340Low131.00KVolume18.280Open18.540Pre Close2.32MTurnover1.66%Turnover Ratio5.01P/E (Static)10.80MShares36.84052wk High1.00P/B137.96MFloat Cap15.30052wk Low--Dividend TTM7.92MShs Float298.567Historical High--Div YieldTTM5.77%Amplitude3.000Historical Low17.712Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
JAKKS Pacific (JAKK) Partners With Aniplex for Demon Slayer
JAKKS Pacific's Disguise Unit Signs Multi-Year Licensing Deal With Aniplex of America
JAKKS Pacific's (JAKK) Disguise business unit said Tuesday that it signed a multi-year licensing agreement with Aniplex of America covering the "Demon Slayer: Kimetsu no Yaiba" animated series in Nort
Express News | Disguise and Aniplex of America Announce New Licensing Agreement for Rights to Demon Slayer: Kimetsu No Yaiba
We Think JAKKS Pacific (NASDAQ:JAKK) Might Have The DNA Of A Multi-Bagger
JAKKS Pacific Bites Into Upcoming Dog Man Movie From DreamWorks/Universal and Dav Pilkey's Global Bestselling Book Franchise for Toys and Costumes
SANTA MONICA, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- JAKKS Pacific, Inc. (NASDAQ:JAKK) and its costume division, Disguise, have partnered with Dav Pilkey to create a line of toys and costumes based on Pilkey's
JAKKS Pacific First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Comments
Despite JAKKS Pacific's low P/E ratio and predicted future earnings growth, investors remain skeptical due to the company's recent earnings instability and potential risks.
Investors Give JAKKS Pacific, Inc. (NASDAQ:JAKK) Shares A 26% HidingDespite recent share price pullback, the business is doing well enough to support the current price. The transition from loss to profitability justifies a strong share price gain. The share price momentum remains strong, suggesting a closer look at the stock might be worth it.
With shrinking earnings, JAKKS Pacific's low P/E ratio is justified. The potential for earnings improvement isn't seen as enough for a higher P/E ratio, leading to skepticism about significant share price growth.
Gainers:
• $Belite Bio(BLTE.US$ +17.49% (announces that LBS-008 an orally administered tablet has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of STGD1)
• $Atkore(ATKR.US$ +12.11% (earnings reports)
• $AST SpaceMobile(ASTS.US$ +9.30% (receives experimental license from FCC for BlueWalker 3 satellite testing)
• $Harmonic(HLIT.US$ +7.56% (earnings reports)
• $The Chemours(CC.US$ +7.2% ...
• $Belite Bio(BLTE.US$ +17.49% (announces that LBS-008 an orally administered tablet has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of STGD1)
• $Atkore(ATKR.US$ +12.11% (earnings reports)
• $AST SpaceMobile(ASTS.US$ +9.30% (receives experimental license from FCC for BlueWalker 3 satellite testing)
• $Harmonic(HLIT.US$ +7.56% (earnings reports)
• $The Chemours(CC.US$ +7.2% ...
17
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg